Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 370,533 trials in your specialties ()
View trials across your selected specialties

The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Brain Tumor
View Full Trial
INTERVENTION

Drug: abemaciclib, Drug: abemaciclib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States

Brief Summary

The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Melanoma
View Full Trial
INTERVENTION

Diagnostic Test: FDG PET/CT scan, Diagnostic Test: C11-AMT PET scan, Drug: Pembrolizumab, Diagnostic Test: FDG PET/CT scan with IV contrast

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Brief Summary

Explore association between intensity of C11-AMT PET at baseline, as measured by mean standardized uptake value (SUVmax at each lesion), total tumor metabolic volume, measurement of intra-tumoral and inter-lesional heterogeneity), with objective response rate (ORR) at 12 weeks (as defined via RECIST 1.1) to pembrolizumab in patients with treatment-naïve metastatic melanoma.

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Epilepsy
View Full Trial
INTERVENTION

Drug: perampanel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Children's of Alabama, Birmingham, Alabama, United States

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants from 1 month to less than 4 years of age with epilepsy.

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Melanoma
View Full Trial
INTERVENTION

Drug: Cobimetinib, Drug: Vemurafenib, Drug: Atezolizumab, Drug: Atezolizumab Placebo, Drug: Vemurafenib Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UZ Leuven Gasthuisberg, Leuven, Belgium

Brief Summary

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioblastoma
View Full Trial
INTERVENTION

Drug: hrBMP4

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Brief Summary

The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Leukemia, Lymphoma, Myelodysplasia
View Full Trial
INTERVENTION

Device: Alpha Beta T cell depletion

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Brief Summary

This is a single arm pilot study for patients using α/β T cell-depleted PSCT in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one year leukemia free survival.

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

  • Status
    Recruiting
  • Phase
    Early Phase 1
  • Condition
    Breast Cancer
View Full Trial
INTERVENTION

Drug: Fluorestradiol (FES), Procedure: PET/CT Imaging

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study is being performed to imaging the amount of estrogen receptors expressed in the tumor. A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them. Then tumors with estrogen receptors can be imaged by a PET/CT scanner, a machine that can take pictures of where the FES is and how much FES is present. The results of this study may help researchers know whether FES can be used to monitor changes in estrogen receptors in tumors during treatment.

Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Cardiac Involvement, Autologous Stem Cell Transplantation, Sclero...
View Full Trial
INTERVENTION

Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology, Tuebingen, Germany

Brief Summary

Autologous stem cell therapy has been shown to be effective in patients with systemic sclerosis. Nevertheless treatment is associated with treatment related mortality and patients die during follow up despite successful transplantation. Intention of this trial is to improve overall survival by modifying the existing protocol used for the ASTIS trial. To reduce treatment toxicity we reduce the dose of Cyclophosphamide (CYC) for mobilisation to 2x1g. Especially in patients with cardiac manifestations we also modify the conditioning regimen by adding thiotepa and reducing CYC; as CYC has known cardiotoxic side effects.

A Study of PY314 in Subjects With Advanced Solid Tumors

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Advanced Solid Tumor
View Full Trial
INTERVENTION

Drug: Dose of PY314

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Honor Health Research Institute, Scottsdale, Arizona, United States

Brief Summary

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome

  • Status
    Not yet recruiting
  • Phase
    Phase 3
  • Condition
    Irritable Bowel Syndrome
View Full Trial
INTERVENTION

Biological: Fecal microbiota transplantation (FMT)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Many patients with irritable bowel syndrome (IBS) do not experience adequate symptom relief with current treatments. The pathophysiology of IBS is diverse, controversial and not completely understood. The next disruptive frontier would be to find a cure where the effect is predictable and lasting. The study groups phase 2 pilot trial was the first indication of a possible benefit from treating IBS with fecal microbiota transplantation (FMT) (Number needed to treat only five) (Fecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-centre trial he Lancet Gastroenterology and Hepatology 2018). Additional results from the same trial show that the treatment response may be predicted (unpublished data), and that the pathophysiologic mechanisms behind the treatment response also can be identified (Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome, Gut Microbes 2020). This study is the first phase 3 trial of FMT for IBS worldwide. The hypothesis of the trial is that donor FMT is more effective than placebo FMT in treating IBS, with little adverse events or complications. Patients ≥18 years with IBS are enrolled at five Norwegian Hospitals in this double blind randomized, placebo controlled, parallell-group multi center trial. Participants are randomized to FMT from a healthy donor (intervention group), or their own feces (placebo group). The primary outcome is the proportion of patients with ≥75 points decrease in the Irritable bowel Symptom Severity score 90 days after treatment.